noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

Pharmaceuticals and Biotechnology

FDA - Food and Drug Administration

Nature's Own (Nature's Own Hawaiian Bread, 20oz single loaf and 40 oz[...]
Philogen S.p.A.

05 Ottobre 2026 – Aggiornamento sul programma di acquisto di azioni proprie
AstraZeneca Pharmaceuticals LP

AstraZeneca opens new global strategic R&D center in Kendall Square,[...]

Economy, Business and Finance

Nuclidium AG

10/05/2026 | Press release | Distributed by Public on 10/05/2026 10:16

NUCLIDIUM is a 2026 Fierce 15 Honoree

Being named to the #Fierce15 recognizes our work to bring the next wave of targeted radiotheranostics to more patients. This honor reflects both the scientific strength of our approach and the commitment of our team to push the boundaries of what radiotheranostics can offer to patients in areas of significant unmet need.

With our lead programs NU101 and NU201 advancing in prostate and breast cancer, 2026 is a year of steady momentum and purposeful drive.

We would like to thank the Fierce Biotech team for selecting us as one of this year's fiercest companies and placing NUCLIDIUM among the most innovative and promising biotech companies within our industry.

The full feature is available here https://lnkd.in/d3craihN

Nuclidium AG published this content on October 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 05, 2026 at 16:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format